In this first reported Phase 1b cohort, the etrumadenant-based combination was well tolerated with a composite overall response rate (ORR) of 41% in people previously treated for metastatic ...
Development of a new, sensitive assay for circulating tumor cell detection in prostate cancer. Background: To evaluate acute and late genitourinary (GU) and gastrointestinal (GI) toxicity and ...
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced initial efficacy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results